Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants-Case Series and Systematic Review of Reported Cases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F15%3A00064387" target="_blank" >RIV/00159816:_____/15:00064387 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.07.021" target="_blank" >http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.07.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.07.021" target="_blank" >10.1016/j.jstrokecerebrovasdis.2015.07.021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants-Case Series and Systematic Review of Reported Cases

Popis výsledku v původním jazyce

Background: Current guidelines do not recommend the administration of intravenous tissue plasminogen activator (IV-tPA) to patients with acute ischemic stroke (AIS) who take new oral anticoagulants (NOACs). We present a multicenter case series of IV-tPAuse while the patients are on NOACs, as well as a systematic review of the literature. Methods: We reviewed the medical records of consecutive patients on NOACs who received IV-tPA for symptoms of AIS at four participating stroke centers in the United States and Europe. Safety endpoints were post-thrombolysis symptomatic intracranial hemorrhage (sICH) or other serious systemic bleeding. Results: Between October 2010 and October 2014, 6 patients received IV-tPA for possible AIS while taking dabigatran. None of the patients had sICH or any other hemorrhagic complication. Literature review resulted in a total of 26 patients receiving IV-tPA while on NOACs (dabigatran: 15, rivaroxaban: 10, apixaban: 1). Among them, two patients experienced

Název v anglickém jazyce

Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants-Case Series and Systematic Review of Reported Cases

Popis výsledku anglicky

Background: Current guidelines do not recommend the administration of intravenous tissue plasminogen activator (IV-tPA) to patients with acute ischemic stroke (AIS) who take new oral anticoagulants (NOACs). We present a multicenter case series of IV-tPAuse while the patients are on NOACs, as well as a systematic review of the literature. Methods: We reviewed the medical records of consecutive patients on NOACs who received IV-tPA for symptoms of AIS at four participating stroke centers in the United States and Europe. Safety endpoints were post-thrombolysis symptomatic intracranial hemorrhage (sICH) or other serious systemic bleeding. Results: Between October 2010 and October 2014, 6 patients received IV-tPA for possible AIS while taking dabigatran. None of the patients had sICH or any other hemorrhagic complication. Literature review resulted in a total of 26 patients receiving IV-tPA while on NOACs (dabigatran: 15, rivaroxaban: 10, apixaban: 1). Among them, two patients experienced

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: Fakultní nemocnice u sv. Anny v Brně - Mezinárodní centrum klinického výzkumu (FNUSA - ICRC)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Stroke &amp; Cerebrovascular Diseases

ISSN

1052-3057

e-ISSN

—

Svazek periodika

24

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

9

Strana od-do

2685-2693

Kód UT WoS článku

000367388800007

EID výsledku v databázi Scopus

—